The psychedelic pipeline has a distinctive shape: a wide Phase 2 and a narrow Phase 3, with programs that entered clinical development years ago still sitting where they started. This piece treats that observation as a data question rather than a vibe. Using ClinicalTrials.gov records for psychedelic-assisted therapy programs, it maps where each program actually is, tracks the 2020 cohort forward five years, and asks why so few have advanced — and what would clear the jam.
What ClinicalTrials.gov shows
A structured pull of psychedelic trial records gives the baseline. [Stub: describe the query — compounds, conditions, phase fields — and summarize the present distribution of programs by phase. Note data caveats: registration lag, terminated-but-not-updated records.]
The 2020 cohort: where they are now
Following a fixed cohort forward isolates advancement from new entry. [Stub: define the cohort of programs in Phase 2 as of 2020 and report how many advanced, stalled, terminated, or remain in Phase 2 today.]
Programs that have advanced
A small number broke through to Phase 3. [Stub: profile the advancers — COMP360, MM120, CYB003 — and identify what they had in common, e.g. capital, trial architecture, or a single lead indication.]
Programs that have stalled
The larger group has not moved. [Stub: characterize the stalled set without singling out failure unfairly; group by apparent cause — funding, readout, strategic pivot.]
Structural reasons for the bottleneck
Why Phase 2 → Phase 3 is unusually hard for this class. [Stub: cover the cost of therapist-delivered designs, the expectancy/methods problem that complicates a clean Phase 2 signal, capital scarcity post-2022, and regulatory uncertainty.]
What would clear it
The conditions under which the cohort starts moving again. [Stub: connect to the FDA draft guidance, capital cycle, and design fixes; what a clearing of the bottleneck would look like in the data.]
Behavioral Wire’s research desk publishes methods references and data analyses. Reporting is held to standards of attribution and verification described in our methodology.